Dopamine News and Research

Latest Dopamine News and Research

Holiday healthy eating reminders from Greenwich Hospital

As holiday crunch time fills your schedule, don't give up your exercise. "When times get crazy, the thing people give up is exercise, and that's the key thing a person needs. When a person is excitable from stress, the burst of energy that you get from exercise can help burn the adrenaline off and calm you down," said Erica Christ, RD, CDE, an exercise physiologist at Greenwich Hospital's Weight Loss & Diabetes Center.

22 Nov 2012

Health professionals may soon have new method to diagnose Parkinson's

Health professionals may soon have a new method of diagnosing Parkinson's disease, one that is noninvasive and inexpensive, and, in early testing, has proved to be effective more than 90 percent of the time.

21 Nov 2012

NeuroDerm initiates enrollment in ND0612 Phase I trial for Parkinson's

NeuroDerm, Ltd. announced today that enrollment of healthy subjects is ongoing in its Phase I clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula administered continuously via a subcutaneous delivery patch device. It is designed to provide steady levodopa blood levels and enhanced bioavailability of oral levodopa for the reduction of motor complications in Parkinson's disease.

21 Nov 2012

IL-13 receptor system could play a major role in Parkinson's

Deciphering what causes the brain cell degeneration of Parkinson's disease has remained a perplexing challenge for scientists. But a team led by scientists from The Scripps Research Institute (TSRI) has pinpointed a key factor controlling damage to brain cells in a mouse model of Parkinson's disease.

20 Nov 2012

Study shows how Parkinson's spreads and leads to nerve cell death

Understanding how any disease progresses is one of the first and most important steps towards finding treatments to stop it. This has been the case for such brain-degenerating conditions as Alzheimer's disease. Now, after several years of incremental study, researchers at the Perelman School of Medicine, University of Pennsylvania have been able to piece together important steps in how Parkinson's disease (PD) spreads from cell to cell and leads to nerve cell death.

17 Nov 2012

Bradykinesia is ‘context-specific’ in Parkinson’s

Patients with Parkinson’s disease can make rapid responses to avoid adverse stimuli, but cannot speed up their actions to gain a reward, report UK researchers.

16 Nov 2012

Feinstein seeks NDA approval for Fluorodopa F 18 PET scan to diagnose parkinsonian syndromes

The Feinstein Institute for Medical Research announced today the submission of a New Drug Application to the US Food and Drug Administration (FDA) for the Fluorodopa F 18 positron emission tomography (PET) scan used to diagnose parkinsonian syndromes.

15 Nov 2012

AKT1 genotype influences risk of psychotic disorders in cannabis users

The ability of cannabis to produce psychosis has long been an important public health concern. This concern is growing in importance as there is emerging data that cannabis exposure during adolescence may increase the risk of developing schizophrenia, a serious psychotic disorder. Further, with the advent of medical marijuana, a new group of people with uncertain psychosis risk may be exposed to cannabis.

15 Nov 2012

Dopamine improves long-term memory

The feel-good hormone dopamine improves long-term memory. This is the finding of a team lead by Emrah D-zel, neuroscientist at the German Center for Neurodegenerative Diseases and the University of Magdeburg.

9 Nov 2012

Genetic underpinning of placebo effect identified

US researchers have identified a gene that appears to be responsible for the placebo effect.

1 Nov 2012

Additional data from EnVivo’s EVP-6124 Phase 2b trial on AD presented at CTAD meeting

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today presented pharmacokinetic and pharmacodynamic data along with the previously reported statistically significant clinical results from its Phase 2b clinical trial of EVP-6124, a novel alpha-7 agonist, in patients with Alzheimer's disease.

1 Nov 2012

FDA accepts Sunovion’s two LATUDA sNDAs for review

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).

31 Oct 2012

Light-sensitive protein to study Parkinson's disease

Introducing a light-sensitive protein in transgenic nerve cells... transplanting nerve cells into the brains of laboratory animals... inserting an optic fibre in the brain and using it to light up the nerve cells and stimulate them into releasing more dopamine to combat Parkinson's disease...

29 Oct 2012

Omega-3 fatty acid can enhance cognition in highly functional young individuals

While Omega-3 essential fatty acids-found in foods like wild fish and grass-fed livestock-are necessary for human body functioning, their effects on the working memory of healthy young adults have not been studied until now.

26 Oct 2012

BioLineRx intends to conduct interim analysis of BL-1020 Phase II/III trial for schizophrenia

BioLineRx, a biopharmaceutical development company, announced today that it intends to conduct an interim analysis of the Phase II/III CLARITY trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.

25 Oct 2012